Key takeaways
- Mechanism: CAR T cells are engineered to target specific cancer cells and can provide long-lasting immune protection, while NK cells naturally recognize and destroy abnormal cells, allowing them to respond without prior sensitization.
- Delivery: Most CAR T therapies are made from a patient's own cells, making treatment highly personalized but complex to manufacture. Many NK cell therapies are being developed as off-the-shelf products that can be given to multiple patients.
- Manufacturing: CAR T therapies are typically produced for one patient at a time, whereas a single donor has the potential to provide enough NK cells to manufacture treatments for many patients, improving scalability and reducing costs.
- Outlook: CAR T therapies are likely to remain a key treatment for certain blood cancers, while NK cell therapies could make cell therapy more widely available thanks to their safety profile, simpler manufacturing, and off-the-shelf potential.
The era of living drugs
Over the past decade, cell therapies have transformed cancer treatment. Rather than relying solely on drugs that directly kill rapidly dividing cells, researchers are increasingly engineering the immune system itself to recognize and eliminate cancer. These "living drugs" — immune cells collected, modified, and returned to the patient — have fundamentally changed expectations for what is possible in oncology.
At the forefront of this shift has been chimeric antigen receptor T cell (CAR T) therapy. Since the first CAR T approval in 2017, the field has expanded rapidly, delivering durable responses in patients with blood cancers who previously had few treatment options. Yet despite its clinical success, CAR T therapy remains constrained by complex manufacturing, high costs, and potentially severe toxicities, limiting access for many patients.
These challenges have fueled growing interest in natural killer (NK) cell therapies. Unlike CAR T therapies, many NK cell platforms are being developed as off-the-shelf products that can be manufactured in advance and administered to multiple patients. Combined with a generally favorable safety profile, this has positioned NK cells as one of the fastest-growing areas of cell therapy research.
The case for CAR T
The defining advantage of CAR-T therapy is its durability.
CAR T cells are derived from T cells, which play a central role in the adaptive immune system. By engineering these cells to express a CAR that recognizes a specific tumor antigen, researchers create a therapy capable of precisely targeting cancer cells. Once infused, CAR T cells can expand dramatically within the patient, eliminating malignant cells before persisting as long-lived memory T cells that continue to provide immune surveillance.
This ability to persist distinguishes CAR T from many other cancer therapies. Even after a patient achieves remission, residual CAR T cells can continue monitoring for cancer recurrence, helping to maintain long-term disease control. For some patients with relapsed or refractory blood cancers, this has translated into durable remissions lasting years.
The prospect of long-term disease control underpins the value proposition of CAR T therapy. Although treatments such as Yescarta and Kymriah are among the most expensive cancer therapies available, they have demonstrated the potential to produce lasting responses in patients who previously had few effective treatment options. Combined with an established regulatory pathway and growing clinical experience, these outcomes have made CAR T the benchmark against which emerging cell therapies are increasingly measured.
The case for NK cells
The appeal of NK cell therapies lies in their potential to overcome many of the practical limitations that have slowed broader adoption of CAR T.
NK cells are part of the innate immune system, providing a rapid first line of defense against infected and malignant cells. Unlike T cells, which recognize specific antigens through their receptors, NK cells respond to a balance of activating and inhibitory signals, allowing them to identify and eliminate abnormal cells without prior sensitization. They are also able to target tumor cells that have reduced expression of major histocompatibility complex Class I molecules — a common mechanism cancers use to evade T-cell recognition.
Equally important is their safety profile. Whereas donor-derived T cells can trigger graft-versus-host disease, NK cells have a much lower risk of causing this complication. As a result, many developers are pursuing allogeneic, donor-derived NK cell therapies that can be manufactured in advance and stored until needed.
This off-the-shelf approach could fundamentally change how cell therapies are delivered. Instead of collecting and engineering a patient's own cells before treatment — a process that can take several weeks — NK cell therapies could be available for immediate use, reducing manufacturing complexity, shortening treatment timelines, and potentially lowering costs. If successful, this model could make cell therapies more accessible to a much broader patient population.
Comparing the platforms
Rather than asking which platform is "better," the more useful question is where each technology offers the greatest advantage. CAR T and NK cell therapies differ in several key areas that will influence their clinical use and commercial success.
Delivery logistics
Autologous CAR T therapies require a complex vein-to-vein manufacturing process. A patient's T cells must be collected, shipped to a manufacturing facility, genetically engineered, expanded, tested, and returned for infusion — a process that can take several weeks and requires careful coordination throughout.
Many NK cell therapies, by contrast, are being developed as allogeneic products. Cells from healthy donors, umbilical cord blood, or induced pluripotent stem cell (iPSC) lines can be manufactured in advance, cryopreserved, and distributed to treatment centers as needed. This approach has the potential to simplify logistics and reduce the time between diagnosis and treatment.
Manufacturing economics
The personalized nature of autologous CAR T manufacturing contributes to its high cost. Because each treatment is produced for a single patient, manufacturing is labor-intensive, capacity is limited, and scaling production remains challenging.
Allogeneic NK cell therapies offer a different manufacturing model. A single donor or iPSC master cell bank has the potential to generate large numbers of therapeutic doses, improving manufacturing efficiency and reducing the cost per treatment. Whether these savings ultimately translate into lower prices will depend on clinical outcomes and commercial factors, but the underlying production model is inherently more scalable.
Safety and treatment setting
CAR-T therapies have demonstrated remarkable efficacy, but they are also associated with serious adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Managing these toxicities often requires specialized clinical expertise and limits treatment to experienced centers.
Early clinical experience suggests NK cell therapies may have a more favorable safety profile, with lower rates of severe CRS and neurotoxicity. If these findings continue to hold in larger studies, NK therapies could be administered in a broader range of healthcare settings, potentially expanding access to cell therapy beyond major academic medical centers.
Tale of the tape
How do these two heavyweights compare head-to-head?
Feature | CAR T Therapy | NK Cell Therapy |
Immune mechanism | Engineered T cells target specific tumor antigens and can provide long-term immune surveillance. | NK cells recognize and eliminate abnormal cells through innate immune mechanisms, with or without CAR engineering. |
Key advantage | Durable responses driven by long-term persistence. | Off-the-shelf potential with a favorable safety profile. |
Cell source | Usually autologous (patient-derived). | Commonly allogeneic (healthy donors, cord blood, or iPSC-derived). |
Manufacturing | Individualized production for each patient. | Large-scale manufacturing for multiple patients. |
Major Safety Risks | Higher risk of cytokine release syndrome (CRS) and neurotoxicity (ICANS). | Lower rates of severe CRS and neurotoxicity reported to date, although persistence may be more limited. |
Turnaround Time | 2-4 weeks (Vein-to-vein). | Immediate (Off-the-shelf). |
Tumor Recognition | Targets predefined antigens but can be affected by antigen loss. | Can recognize stressed cells and those with reduced MHC Class I expression, in addition to CAR-directed targeting. |
The convergence
The distinction between CAR T and NK cell therapies is already beginning to blur as developers combine the strengths of both platforms.
One of the most active areas of research is CAR-NK therapy, which equips NK cells with a chimeric antigen receptor to improve tumor targeting while retaining the favorable safety profile associated with NK cells. Early clinical studies suggest CAR-NK therapies may offer the precision of CAR T with the potential advantages of allogeneic manufacturing and reduced toxicity.
At the same time, developers are working to address the limitations of CAR T. Gene-editing technologies such as CRISPR/Cas9 are enabling the development of allogeneic CAR T products designed to eliminate the need for patient-specific manufacturing. Although these "off-the-shelf" CAR-T therapies remain in development, challenges such as immune rejection and long-term persistence still need to be overcome.
Researchers are also engineering NK cells to overcome one of their biggest limitations: persistence. By incorporating cytokines such as IL-15 or other supportive signals, next-generation NK therapies aim to survive longer in the body while maintaining their favorable safety profile.
Rather than converging on a single platform, the field is evolving toward a spectrum of engineered immune cells, each designed to balance efficacy, persistence, safety, and manufacturability for different clinical settings.
Different strengths for different patients
CAR T therapies have established themselves as one of the most effective treatments for certain relapsed and refractory blood cancers, delivering durable responses that were previously difficult to achieve. Their ability to persist in the body continues to make them an important option when long-term disease control is the primary goal.
NK cell therapies, meanwhile, are being developed to address many of the practical challenges associated with CAR T. Their potential for off-the-shelf manufacturing, simplified logistics, and favorable safety profile could expand access to cell therapy and make it feasible to treat patients in a wider range of healthcare settings.
Whether NK therapies ultimately move into earlier lines of treatment or prove particularly effective against solid tumors remains an open question that ongoing clinical trials will answer. What is already clear, however, is that the field is moving beyond a one-size-fits-all approach.
The future of cell therapy is unlikely to be defined by a single winning platform. Instead, it will be shaped by a growing portfolio of engineered immune cells, with different technologies suited to different diseases, patient populations, and treatment settings. As developers continue to refine both CAR T and NK cell therapies—and increasingly combine features of each — the question is becoming less about choosing between them and more about identifying the right cell for the right patient at the right time.
This article was produced in accordance with Drug Discovery News’ Editorial Policies.
